OakChart

Scynexis Inc

SCYXHealthcare·Drug Manufacturers - Specialty & Generic·USA·Nano·NASD·Nov 11 • 3:59 PM ET

3.41-0.11 (-2.98%)
2026-11-11 22:09 CET
Market cap
35.04 USD m
Revenue, TTM
18.88 USD m
Net income, TTM
-10.10 USD m
Free cash flow, TTM
-12.05 USD m
EPS diluted, TTM
-1.18
P/E
-
Compare

Price

SCYX against its 20, 50 and 200-day averages
2050200beatmiss
4.006.008.003.9M7.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SCYXclose 3.4220-day 3.7250-day 4.29200-day 5.463.42

62.6% under the 52-week high of 9.12 on 15 Apr 2026. 52-week low 3.28 on 5 Nov 2026. Last 15 sessions, 23.2% high to low

Volume 0.28× normal · the line is the 50-bar volume average

Profile

SCYX
52-week range, 2% of the way up
3.289.12

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Employees18
IPOMay 02, 2014
Beta1.23
ATR, 14d0.27
Rel volume0.28
Short float4.71%
Insider own3.96%
Inst own56.69%

Snapshot

6 groups

Valuation

Index-
Market Cap33.99M
Enterprise Value-11.49M
Income-10.10M
Sales18.88M
Book/sh5.93
Cash/sh4.75
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees18
IPOMay 02, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S1.80
P/B0.58
P/C0.72
P/FCF-
EV/EBITDA-
EV/Sales-0.61
Quick Ratio7.48
Current Ratio7.48
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.18
EPS next Y-1.95
EPS next Q-0.63
EPS this Y-130.15%
EPS next Y37.59%
EPS next 5Y-8.35%
EPS past 3/5Y51.09% 49.30%
Sales past 3/5Y59.35% -
EPS Y/Y TTM72.49%
Sales Y/Y TTM543.96%
EPS Q/Q48.15%
Sales Q/Q-100.00%
EarningsNov 05 BMO
EPS/Sales Surpr.1.39% -100.00%

Ownership

Insider Own3.96%
Insider Trans0.00%
Inst Own56.69%
Inst Trans13.06%
ROA-16.98%
ROE-21.16%
ROIC-16.75%
Gross Margin-
Oper. Margin-126.87%
Profit Margin-53.50%
SMA20-8.24%
SMA50-20.32%
SMA200-37.41%
Trades-

Technical

Shs Outstand9.95M
Shs Float9.56M
Short Float4.71%
Short Ratio2.02
Short Interest0.45M
52W High9.12 -62.55%
52W Low3.28 4.11%
Volatility7.01% 5.80%
ATR (14)0.27
RSI (14)35.52
Beta1.23
Rel Volume0.28
Avg Volume222.49K
Volume61,970

Performance

Perf Week-11.07%
Perf Month-14.41%
Perf Quarter-33.30%
Perf Half Y-43.89%
Perf YTD-32.50%
Perf Year-28.96%
Perf 3Y-74.96%
Perf 5Y-91.90%
Perf 10Y-98.83%
Recom1.00
Target Price32.67
Prev Close3.52
Price3.41
Change %-2.98%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jan 22, 2021InitiatedGGuggenheimBuy$25+632.1%
Jan 06, 2021InitiatedCCantor FitzgeraldOverweight$30+778.5%
Jul 11, 2018UpgradeNNeedhamHold → Buy$5+46.4%
Jun 27, 2018InitiatedMMaxim GroupBuy$6+75.7%
Oct 24, 2017InitiatedGGuggenheimBuy$6+75.7%
Jul 10, 2017InitiatedRROTH CapitalBuy$8.50+148.9%
May 09, 2017DowngradeNNeedhamBuy → Hold
Mar 03, 2017ReiteratedRRBC Capital MktsOutperform$15 → $11+222.1%
Oct 20, 2016InitiatedHH.C. WainwrightBuy$14+310.0%
Oct 07, 2016UpgradeWWBB SecuritiesBuy → Strong Buy$8+134.3%

Peers

Mkt cap
TickerCompanyMkt cap
CPIXCumberland Pharmaceuticals Inc91.70M
MTNBMatinas Biopharma Holdings Inc0.88M
SPROSpero Therapeutics Inc59.40M
DAREDare Bioscience Inc13.65M
ARMPArmata Pharmaceuticals Inc142.22M
ACXPAcurx Pharmaceuticals Inc5.72M
ANTXAN2 Therapeutics Inc169.23M
TNXPTonix Pharmaceuticals Holding Corp75.20M
FEMYFemasys Inc12.57M
VIRVir Biotechnology Inc2.25B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
BSVOEA Bridgeway Omni Small-Cap Value ETFAUM: 2.44B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M

News

latest 14 of 200
  • Scynexis: Q3 Earnings Snapshot (Associated Press) -14.06%
  • SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference (GlobeNewswire)
  • SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases (GlobeNewswire)
  • SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek (GlobeNewswire)
  • SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire)
  • Scynexis stock surges on $214M BARDA contract for SCY-247 (Investing.com) +5.24%
  • Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract (InvestorsHub)
  • SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 (GlobeNewswire)
  • SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors (GlobeNewswire) +10.45%
  • SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development (GlobeNewswire)
  • SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer (GlobeNewswire)
  • SCYNEXIS to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.25%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.710-0.720-0.7100.000.132
2026Q22026-08-100.630-0.5070.6260.240.083
2026Q12026-05-11-3.360-0.987-3.3440.000.083
2025Q42026-03-042.0001.0142.25218.658.103
2025Q32025-11-05-1.360-1.600-1.3770.330.133
2025Q22025-08-13-1.120-1.520-1.1071.360.153
2025Q12025-05-15-0.880-1.546-0.8720.260.143
2024Q42025-03-12-0.720-0.160-0.9340.9810.193
2024Q32024-11-06-0.480-1.146-0.4620.666.186
2024Q22024-08-08-2.400-1.536-2.3840.740.285
2024Q12024-05-080.080-1.4720.0681.370.245
2023Q42024-03-28-2.560-0.460-4.5205.807.654
2023Q32023-11-13-0.320-1.072-0.2941.765.895
2023Q22023-08-1419.68011.61619.661131.4595.405
2023Q12023-05-11-5.680-2.800-5.6751.130.865
2022Q42023-03-31-2.400-2.860-3.5321.401.154

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-76.800-63.066-76.6180.120.13
2020FY-41.200-12.617-41.1820.000.00
2021FY-10.000-7.974-9.96513.1611.80
2022FY-11.760-11.260-11.7915.004.71
2023FY11.12012.74011.083140.14141.89
2024FY-3.520-3.466-3.5113.7512.96
2025FY-1.360-2.507-1.36020.609.94
2026FY--3.130--0.39
2027FY--1.953--6.52
2028FY--1.730--14.08
2029FY--2.580--12.63
2030FY--2.960--27.60

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-053110.160.000.48
2026Q4S2026-10-062010.140.000.27
2026Q4S2026-08-232100.240.000.48
2026Q4S2026-08-123100.980.002.46
2026Q4S2026-08-113000.910.002.46
2026Q4S2026-05-293000.910.002.46
2026Q4S2026-05-203010.910.002.46
2026Q4S2026-05-123020.910.002.46
2026Q4S2026-04-143020.910.002.46
2026Q4S2026-04-133020.910.002.46
2026Q4S2026-03-183020.910.002.46
2026Q4S2026-03-173020.910.002.46
2026Q4S2026-03-062011.230.002.46
2026Q4S2025-12-062000.270.200.33

Estimate history

EPS, annual-75.2-22.729-76.618-41.182-9.965-11.79111.083-3.511-1.379-1.1803
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.462-0.934-0.872-1.107-1.3772.252-3.3440.626-0.714
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.2570.2570.121013.1635.091140.1413.74620.60118.88
Period201720182019202020212022202320242025TTM
Sales, quarterly0.660.9770.2571.3640.33418.64600.2350
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.3620.61.2182.4583.5884.0854.6514.7475.4439.953
Period201720182019202020212022202320242025MRQ
Shares, quarterly4.7434.7474.8784.8975.2455.4437.7569.959.953
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue18.8820.603.75140.145.0913.160.000.120.26
Cost of Goods Sold Incl. D&A---16.431.440.890.30--
Gross Profit---123.713.6512.27-0.30--
Selling, General and Administrative Excl. Other42.8436.6740.8651.0489.4173.1150.8548.7630.19
Research and Development26.9922.2826.4130.9327.2623.7736.5238.3921.56
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-23.95-16.07-37.1272.67-85.76-60.84-51.15-48.92-29.98
Interest Expense0.000.482.556.126.793.962.382.162.05
Unusual Expense-10.04-5.77-14.013.32-23.62-28.814.723.98-11.87
Net Income Before Taxes-10.10-8.61-21.1467.18-67.51-35.95-58.33-53.71-19.20
Income Taxes0.000.000.150.14-4.70-3.09-3.150.00-6.74
Consolidated Net Income-10.10-8.61-21.2967.04-62.81-32.87-55.19-53.71-12.47
Net Income From Continuing Operations-10.10-8.61-21.2967.04-62.81-32.87-55.19-53.71-12.47
Net Income-10.10-8.61-21.2967.04-62.81-32.87-55.19-53.71-12.47
EPS (Recurring)-1.45-2.03-5.1311.47-14.89-16.08-38.71-72.65-37.87
EPS (Basic, Before Extraordinaries)-1.18-1.38-3.5111.21-11.79-9.97-41.18-76.62-22.73
EPS (Diluted)-1.18-1.38-3.5111.08-11.79-9.97-41.18-76.62-22.73
EBITDA-23.95-16.07-37.1273.48-84.94-60.26-50.85-48.64-29.93
Non-Operating Income (Expense)3.812.184.533.951.420.04-0.081.340.97
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.402.853.352.623.512.092.221.831.43
Price To Earnings Ratio---1.76-----
Price To Sales Ratio3.101.5315.670.7713.0612.23-421.7782.25
Gross Margin---88.2771.7093.25---
Operating Margin-126.87-78.03-990.8451.85-1,684.48-462.19--40,430.58-11,666.54
Net Margin-53.50-41.79-568.2947.84-1,233.73-249.68--44,388.43-4,851.36
Shares Outstanding9.955.444.754.654.093.592.461.220.60
Market Capitalization35.0435.0445.9582.9050.94175.10150.4388.6523.11

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.230.0018.650.331.360.260.98
Cost of Goods Sold Incl. D&A0.00-0.00-----
Gross Profit0.00-0.00-----
Selling, General and Administrative Excl. Other9.768.0116.948.128.7410.938.879.03
Research and Development6.203.8912.354.545.457.145.144.31
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.76-7.78-16.9410.52-8.40-9.56-8.61-8.05
Interest Expense0.000.000.000.000.000.000.480.68
Unusual Expense0.18-14.155.25-1.320.64-2.17-2.93-3.21
Net Income Before Taxes-8.467.40-21.3012.26-8.59-6.88-5.39-4.41
Income Taxes0.000.000.000.000.000.000.000.02
Consolidated Net Income-8.467.40-21.3012.26-8.59-6.88-5.39-4.43
Net Income From Continuing Operations-8.467.40-21.3012.26-8.59-6.88-5.39-4.43
Net Income-8.467.40-21.3012.26-8.59-6.88-5.39-4.43
EPS (Recurring)-0.70-0.21-2.772.08-1.31-1.35-1.20-1.41
EPS (Basic, Before Extraordinaries)-0.710.63-3.342.25-1.38-1.11-0.87-0.93
EPS (Diluted)-0.710.63-3.342.25-1.38-1.11-0.87-0.93
EBITDA-9.76-7.78-16.9410.52-8.40-9.56-8.61-8.05
Non-Operating Income (Expense)1.491.020.890.420.450.510.781.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.560.570.580.690.530.820.820.98
Price To Sales Ratio3.102.502.301.3413.1010.3017.9012.27
Operating Margin--3,308.51-56.42-2,516.47-700.95-3,350.19-824.26
Net Margin-3,147.66-65.74-2,572.16-504.77-2,097.67-453.74
Shares Outstanding9.959.957.765.445.244.904.884.75
Market Capitalization35.0440.4256.8927.5432.3126.4437.1545.95

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments40.1159.7374.7473.56104.4893.0448.4144.2143.89
Short Term Receivables0.0010.2621.832.100.862.880.006.730.25
Inventories0.000.000.000.900.460.000.000.000.00
Other Current Assets0.262.185.552.503.572.293.990.520.82
Total Current Assets40.3772.18102.1279.06109.3898.2152.4051.4644.96
Net Property, Plant & Equipment1.762.092.362.592.913.303.600.520.00
Total Investments and Advances16.3615.9623.760.160.220.270.270.270.00
Intangible Assets0.000.000.000.411.06--0.000.00
Other Assets0.530.420.175.586.270.760.880.920.89
Total Assets59.0390.64128.4187.81119.84102.5457.1553.1745.85
Short Term Debt Incl. Current Port. of LT Debt0.4814.100.346.050.070.050.040.004.35
Accounts Payable2.234.577.155.947.854.647.183.653.83
Other Current Liabilities3.035.438.815.635.7021.703.802.221.96
Total Current Liabilities5.7324.1016.3017.6213.6226.4011.015.8810.14
Long Term Debt1.692.1714.7448.3143.5619.7914.8515.0810.30
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities2.239.2924.4118.6421.4133.5918.400.993.99
Total Liabilities9.6535.5755.4584.5878.5879.7844.2621.9524.44
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity49.3855.0872.963.2341.2622.7612.8931.2321.41
Total Shareholders Equity49.3855.0872.963.2341.2622.7612.8931.2321.41
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity49.3855.0872.963.2341.2622.7612.8931.2321.41
Total Liabilities & Stockholders Equity59.0390.64128.4187.81119.84102.5457.1553.1745.85
Book Value Per Share9.0711.6015.690.7911.509.2610.5952.0759.12
Tangible Book Value Per Share9.0711.6015.690.6911.209.2610.5952.0759.12
Full-Time Employees182829365638272419
Price to Book Ratio0.590.830.902.964.246.616.870.742.41
Return on Assets-11.50-19.4462.01-60.50-29.56-69.12-97.37-25.18-47.44
Return on Equity-16.48-33.25175.97-282.34-102.68-309.57-243.47-47.38-89.14
Return on Invested Capital-16.86-37.1876.44-121.85-38.75-129.70-193.60-26.92-79.02
Quick Ratio7.043.006.264.448.003.724.768.764.43
Current Ratio7.043.006.264.498.033.724.768.764.43

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-10.10-8.61-21.2967.04-62.81-32.87-55.19-53.71-12.47
Depreciation--0.000.810.810.580.300.280.05
Other Funds (Non Cash)-6.62-2.76-10.0022.95-18.65-25.428.756.96-9.51
Funds from Operations-16.73-11.37-31.2990.80-80.65-57.71-46.14-46.47-21.92
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.676.087.28-30.640.763.15-3.228.35-6.40
Cash from Operating Activities-12.05-5.28-24.0160.16-79.88-54.56-49.35-38.12-28.32
Capital Expenditures0.000.000.000.00-0.01-1.17-0.000.00-0.56
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-31.3124.316.15-34.88-27.380.006.4826.24-0.24
Purchase of Investments-58.39-18.90-36.42-85.48-27.380.00-14.23-39.50-85.11
Sale Or Maturity of Investments27.0843.2142.5750.600.000.0020.7165.7484.87
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-31.3124.316.15-34.88-27.39-1.176.4726.24-0.80
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock36.68-0.17-0.14-0.0943.6338.3784.5043.5329.42
Repurchase of Common Pref Stock0.000.000.000.000.000.00-0.210.000.00
Sale of Common Pref Stock36.68-0.17-0.14-0.0943.6338.3784.7043.5329.42
Proceedsfrom Stock Options-3.37-0.22-0.20-0.1443.6138.3584.6743.4829.39
Issuance or Reduction of Debt, Net0.00-14.000.00-36.654.9728.759.51-1.230.00
Change in Long Term Debt0.00-14.000.00-36.654.9728.759.51-1.230.00
Issuance of Long Term Debt0.000.000.000.005.0030.0010.0016.000.00
Reduction of Long Term Debt0.00-14.000.00-36.65-0.03-1.25-0.49-17.230.00
Net Financing Active Other Cash Flow0.110.000.000.020.000.000.000.000.00
Other Financing Activities Uses0.110.000.000.000.000.000.000.000.00
Cash from Financing Activities36.79-14.17-0.14-36.7248.6067.1294.0042.3029.42
Net Change in Cash-6.574.85-18.00-11.44-58.6711.3951.1230.430.30
Free Cash Flow-12.05-5.28-24.01---54.56-49.36-38.12-28.89
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments47.3054.1659.3440.1138.0144.92
Short Term Receivables0.000.000.000.0010.0010.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.431.540.920.260.691.58
Total Current Assets49.7355.7060.2640.3748.6956.50
Net Property, Plant & Equipment1.481.581.671.761.851.93
Total Investments and Advances16.1117.1613.2616.360.111.84
Intangible Assets0.000.000.000.000.000.00
Other Assets0.630.532.430.530.420.42
Total Assets67.9574.9777.6359.0351.0760.69
Short Term Debt Incl. Current Port. of LT Debt0.550.530.500.480.460.44
Accounts Payable3.603.275.632.233.476.17
Other Current Liabilities2.502.039.763.034.544.25
Total Current Liabilities6.655.8315.905.738.4710.86
Long Term Debt1.271.421.561.691.821.95
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.980.8018.862.234.353.42
Total Liabilities8.908.0436.329.6514.6416.23
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity59.0566.9341.3149.3836.4344.47
Total Shareholders Equity59.0566.9341.3149.3836.4344.47
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity59.0566.9341.3149.3836.4344.47
Total Liabilities & Stockholders Equity67.9574.9777.6359.0351.0760.69
Book Value Per Share5.936.735.339.076.959.08
Tangible Book Value Per Share5.936.735.339.076.959.08
Full-Time Employees---18--
Price to Book Ratio0.590.761.380.560.890.59
Return on Assets-16.98-15.09-33.69-11.50-33.71-23.17
Return on Equity-21.16-18.38-53.39-16.48-53.29-37.22
Return on Invested Capital-14.0210.82-49.6924.00-22.46-14.83
Quick Ratio7.489.563.797.045.755.20
Current Ratio7.489.563.797.045.755.20

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-8.467.40-21.3012.26-8.59-6.88
Other Funds (Non Cash)0.77-13.426.63-0.611.15-1.38
Funds from Operations-7.69-6.02-14.6611.65-7.44-8.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.22-8.866.566.75-1.280.77
Cash from Operating Activities-7.47-14.88-8.1018.40-8.72-7.50
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments5.80-24.76-0.53-11.8212.4211.27
Purchase of Investments0.00-36.21-3.27-18.900.000.00
Sale Or Maturity of Investments5.8011.462.757.0812.4211.27
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities5.80-24.76-0.53-11.8212.4211.27
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.5913.4624.04-0.230.030.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.5913.4624.04-0.230.030.00
Proceedsfrom Stock Options-0.61-2.540.00-0.230.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.110.000.00
Other Financing Activities Uses0.000.000.000.110.000.00
Cash from Financing Activities-0.5913.4624.04-0.120.030.00
Net Change in Cash-2.26-26.1815.416.463.723.78
Free Cash Flow-7.47-14.88-8.1018.40-8.72-7.50

Revenue breakdown

License and Service2024: 3.75M 2025: 19.16M
Product2025: 1.44M
United States2024: 3.75M 2025: 20.60M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.71%0.5M9.6M279.75K
2026-10-154.40%0.4M9.6M276.29K
2026-09-306.22%0.6M9.6M264.69K
2026-09-154.81%0.5M9.6M136.71K
2026-08-314.75%0.5M9.6M138.34K
2026-08-144.37%0.4M9.6M135.91K
2026-07-313.57%0.3M9.5M120.70K
2026-07-153.64%0.3M9.5M69.04K
2026-06-303.99%0.4M9.5M85.69K
2026-06-153.36%0.3M9.5M73.99K
2026-05-293.38%0.3M9.5M71.45K
2026-05-152.98%0.3M9.5M68.49K
2026-04-302.76%0.3M9.5M69.03K
2026-04-152.80%0.1M5.2M76.80K
2026-03-312.93%0.2M5.2M72.25K
2026-03-132.77%0.1M5.2M55.41K
2026-02-272.89%0.2M5.2M51.54K
2026-02-132.84%0.1M4.9M60.56K
2026-01-302.86%0.1M4.9M63.04K
2026-01-152.87%0.1M5.0M57.72K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.004.100.000.0000.000.000.899-0.0100.001
call5.000.004.600.100.00030.000.000.558-0.0790.002
call7.500.000.100.053.3011510.000.130-0.0210.001
put2.500.000.050.051.77541.000.00-0.092-0.0090.001
put5.000.052.550.006.6320.000.00-0.442-0.0780.002
put7.501.506.500.0016.3930.000.00-0.870-0.0220.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-09-288-KCurrent report2026-09-25SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-223Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-228-KCurrent report2026-09-18SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-113Initial statement of beneficial ownership of securities2026-09-09SEC
2026-09-108-KCurrent report2026-09-09SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13GSEC
2026-08-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-20SCHEDULE 13G/ASEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-268-KCurrent report2026-06-25SEC
2026-05-298-KCurrent report2026-05-28SEC
2026-05-228-KCurrent report2026-05-19SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-08EFFECTEffectiveness filing by commission orderSEC
2026-05-08424B3SEC
2026-05-06CORRESPSEC
2026-05-06UPLOADUpload SubmissionSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GREAT POINT PARTNERS LLC9.51%
Squadron Capital Management LLC7.62%
ADAGE CAPITAL PARTNERS GP, L.L.C.5.47%
Propel Bio Management, LLC5.47%
Woodline Partners LP3.90%
VANGUARD CAPITAL MANAGEMENT LLC2.99%
Avidity Partners Management LP2.62%
KINGDON CAPITAL MANAGEMENT, L.L.C.2.50%
MILLENNIUM MANAGEMENT LLC1.82%
HEIGHTS CAPITAL MANAGEMENT, INC1.52%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.54%
VANGUARD EXTENDED MARKET INDEX FUND1.29%
Fidelity Extended Market Index Fund0.59%
Fidelity Series Total Market Index Fund0.16%
EA Bridgeway Omni Small-Cap Value ETF0.16%
Fidelity Total Market Index Fund0.15%
VANGUARD BALANCED INDEX FUND0.06%
Fidelity Nasdaq Composite Index Fund0.05%
Dimensional U.S. Small Cap ETF0.05%
U.S. MICRO CAP PORTFOLIO0.05%

OakChart. SCYX. Cached 15 minutes.

Some panels did not load: insider.